Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by jolanta12on Mar 28, 2020 12:39am

213 Views

Post# 30855368

RE:Speed up Clinical Trials for a Coronavirus Vaccine!!

So this is the new official protocol for pandemic vaccines trials!!!!!
This is the answer for bull ....shi.....ters who are telling the stories about 2-5-10 years trials!!!!!
Vaccine will be done within the shortest time available even in few months if is working and gives the cure !!!!
There is no time for tinkering but the world has to come up as fast as possible. The race is on!!!!!

https://www.euroweeklynews.com/2020/03/28/spain-and-norway-speed-up-clinical-trials-for-a-coronavirus-vaccine-in-a-historic-collaboration/

Bullboard Posts

A potential breakthrough in spinal cord and optic nerve injury treatment